{"id":"nucleoside-analog-substance","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Neuropathy"}]},"_chembl":{"chemblId":"CHEMBL2368119","moleculeType":"Unknown","molecularWeight":"1029.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nucleoside analogs are synthetic compounds that structurally resemble natural nucleosides (building blocks of DNA and RNA). Once incorporated into nucleic acid chains during replication, they cause chain termination or introduce mutations, effectively halting the proliferation of rapidly dividing cells such as viruses or cancer cells. This mechanism makes them useful in both antiviral and anticancer therapy.","oneSentence":"Nucleoside analogs inhibit viral or cancer cell replication by mimicking natural nucleosides and disrupting DNA/RNA synthesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:57:53.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06644417","phase":"PHASE2","title":"Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-14","conditions":"HBV Infection With LLV","enrollment":122},{"nctId":"NCT06706310","phase":"PHASE2","title":"Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-12-04","conditions":"Chronic Hepatitis B","enrollment":116},{"nctId":"NCT00005585","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-04","conditions":"Leukemia","enrollment":838},{"nctId":"NCT03801538","phase":"PHASE4","title":"The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-01-01","conditions":"Chronic Hepatitis B","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NAs"],"phase":"marketed","status":"active","brandName":"Nucleoside Analog (Substance)","genericName":"Nucleoside Analog (Substance)","companyName":"Third Affiliated Hospital, Sun Yat-Sen University","companyId":"third-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}